Self-Lubricating Medical Articles
US-2020095515-A1 · Mar 26, 2020 · US
US12370291B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12370291-B2 |
| Application number | US-202217680657-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 25, 2022 |
| Priority date | Feb 25, 2021 |
| Publication date | Jul 29, 2025 |
| Grant date | Jul 29, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Medical articles formed from a polyurethane-based resin including an ionically-charged modifier provide enhanced properties. The polyurethane-based resin is a reaction product of ingredients comprising: a diisocyanate; a diol chain extender; a polyglycol; and an anionic modifier incorporated into a backbone, as a side chain, or both of the polyurethane-based resin. Exemplary anionic modifier includes 2,2-bis(hydroxymethyl)butyric acid (BHMBA) and/or bis-1,4-((2-hydroxypropoxy)-2-propoxy)-butane sulfonate sodium salt (SULFADIOL®-7Q). Medical articles herein either have inherent antimicrobial and/or anti-fouling characteristics or can easily bond cationic active agents to provide desirable material properties, including antimicrobial, anti-fouling, and/or radiopacity.
Opening claim text (preview).
What is claimed is: 1. A medical article formed from a polyurethane-based resin, which is a reaction product of ingredients consisting essentially of: 4,4′-diphenylmethane diisocyanate (MDI) as a diisocyanate; 1,4-butanediol as a diol chain extender; a polytetramethylene ether glycol as a polyglycol; and an anionic modifier incorporated into a backbone, as a side chain, or both of the polyurethane-based resin formed by the diisocyanate, the polyglycol, and the diol chain extender, wherein the anionic modifier comprises bis-1,4-((2-hydroxypropoxy)-2-propoxy)-butane sulfonate sodium salt, the polyurethane-based resin having a hard segment content in a range of from 25% to 75% by weight of the overall resin composition and a soft segment content of the resin is in a range of from 75% to 25% by weight of the overall resin composition. 2. The medical article of claim 1 , which is effective to reduce thrombus formation and/or bacterial biofilm formation. 3. The medical article of claim 2 , which is effective to reduce thrombus formation and/or bacterial biofilm formation due to ionic repulsion of bacteria, protein, and blood components. 4. The medical article of claim 1 , wherein the anionic modifier is present in an amount of greater than or equal to 0.01 weight percent of the overall composition of the polyurethane-based resin. 5. The medical article of claim 1 , wherein the anionic modifier is present in an amount of less than or equal to 75 weight percent of the overall composition of the polyurethane-based resin. 6. The medical article of claim 1 , wherein the polyurethane-based resin is bound to a cationic agent through ionic bonding. 7. The medical article of claim 6 , wherein the ionic bonding is achieved by a technique comprising a solution imbibing technique or a bulk mixing technique. 8. The medical article of claim 7 , wherein the bulk mixing technique comprises a thermal compounding technique and a solvent mixing technique. 9. The medical article of claim 7 , wherein the solution imbibing technique comprises: de-protonating a portion of the anionic modifier, and soaking the polyurethane-based resin in a solution of the cationic agent. 10. The medical article of claim 9 , wherein the solution imbibing technique further comprises: swelling the polyurethane-based resin before the de-protonating of the portion of the anionic modifier, and rinsing the polyurethane-based resin before the soaking of the polyurethane-based resin in a solution of the cationic agent. 11. The medical article of claim 6 , wherein the cationic agent comprises one or more of: an antimicrobial agent, a lubricating agent, a radiopaque agent, and an antithrombotic agent. 12. The medical article of claim 11 comprising the antimicrobial agent, antithrombotic agent, or a combination thereof, which is effective to provide antimicrobial and/or anti-fouling activity. 13. The medical article of claim 12 , which is effective to actively provide enhanced surface properties, the enhanced surface properties comprising antimicrobial and/or anti-fouling activity. 14. The medical article of claim 11 , wherein the cationic agent comprises one or more of: chlorhexidine acetate, chlorhexidine gluconate, silver sulfadiazine, benzalkonium chloride, cetylpyridinium chloride, a cationic quaternary ammonium and guanidine-containing biocide, a cationic antimicrobial polymer, an antimicrobial peptide or peptide-mimics, and an antifouling phospholipid or phospholipid-mimics. 15. The medical article of claim 11 comprising the radiopaque agent comprising barium cations, bismuth cations, or a combination thereof, which is effective to provide medical article radiopacity. 16. The medical article of claim 1 , wherein the ingredients of the reaction product further comprise: a low-surface energy modifying oligomer incorporated into a backbone, as a side chain, or both of the polyurethane-based resin formed by the diisocyanate, the polyglycol, the anionic modifier, and the diol chain extender, the low-surface energy modifying oligomer comprising a diol-containing perfluoropolyether and/or a monofunctional polysiloxane. 17. The medical article of claim 16 , wherein the modifying oligomer has an alcohol (C—OH) moiety and a functional moiety. 18. The medical article of claim 17 , wherein the functional moiety comprises a fluoroether, a silicone, or a combination thereof. 19. The medical article of claim 16 , wherein the low-surface energy modifying oligomer is present in an amount ranging from about 0.1 to about 10 weight percent of the overall composition of the polyurethane-based resin.
containing only one alkylene bisphenyl group · CPC title
Anti-thrombotic agents, anticoagulants, anti-platelet agents · CPC title
by oxygen-containing compounds inclusive of carbonic acid halogenides, carboxylic acid halogenides and epoxy halides (by aldehydes C08G18/84, by peroxides C08G18/86) · CPC title
with compounds of group C08G18/3203 · CPC title
aliphatic · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.